



Cite this: DOI: 10.1039/d2ob01404a

## Algorithm-driven activity-directed expansion of a series of antibacterial quinazolinones†

 Daniel Francis,<sup>a,b</sup> Sannia Farooque,<sup>a,b</sup> Archie Meager,<sup>a,b</sup> Didi Derks,<sup>a</sup> Abbie Leggott,<sup>a,b</sup> Stuart Warriner,<sup>a,b</sup> Alex J. O'Neill<sup>b,c</sup> and Adam Nelson  <sup>\*a,b</sup>

Activity-directed synthesis (ADS) is a structure-blind, function driven approach that can drive the discovery of bioactive small molecules. In ADS, arrays of reactions are designed and executed, and the crude product mixtures are then directly screened to identify reactions that yield bioactive products. The design of subsequent reaction arrays is then informed by the hit reactions that are discovered. In this study, algorithms for reaction array design were developed in which the reactions to be executed were selected from a large set of virtual reactions; the reactions were selected on the basis of similarity to reactions known to yield bioactive products. The algorithms were harnessed to design arrays of photoredox-catalysed alkylation reactions whose crude products were then screened for inhibition of growth of *S. aureus* ATCC29213. It was demonstrated that the approach enabled expansion of a series of antibacterial quinazolinones. It is envisaged that such algorithms could ultimately enable fully autonomous activity-directed molecular discovery.

 Received 2nd August 2022,  
 Accepted 27th October 2022

DOI: 10.1039/d2ob01404a

rsc.li/obc

## Introduction

The discovery of bioactive small molecules is a central challenge in both medicinal chemistry and chemical biology. Within this context, we have developed activity-directed synthesis (ADS),<sup>1</sup> a structure-blind molecular discovery approach<sup>2</sup> in which synthetic routes emerge on the basis of the function of the resulting products. In ADS, arrays of reactions are designed and executed in which different combinations of components (*e.g.* substrates, co-substrates and catalysts) are explored. Here, “promiscuous” reactions – with multiple possible outcomes – may be deliberately harnessed in order to explore diverse chemical space. After evaporation, the crude reaction mixtures are screened directly for biological function. Hit reactions – that yield bioactive products – then inform the design of subsequent reaction arrays. To date, reaction array design has been human-driven (rather than algorithm-driven). A range of different underpinning chemistries and assay types have been harnessed to drive ADS (Scheme 1).<sup>3–6</sup> For example, metal-catalysed diazo chemistry was exploited in the activity-


directed discovery of diverse modulators of androgen receptor (panel A).<sup>3,4</sup> More recently, Pd-catalysed carbonylation chemistry, in conjunction with a phenotypic assay (growth inhibition of *S. aureus*), enabled the expansion of a series of antibacterial quinazolinones (panel B);<sup>5</sup> this series had been developed to target penicillin-binding proteins, and displays promising activity (minimum inhibitory concentrations [MICs] as low as 0.003  $\mu\text{g ml}^{-1}$ ) against multiple strains of *S. aureus*.<sup>7</sup>

We have previously noted<sup>1,8</sup> that the integrated and parallel nature of ADS workflows may facilitate the realisation of fully autonomous molecular discovery. Such a workflow would require the design of reaction arrays to be algorithm-driven, and all experimental activities to be automated and integrated. In this study, we describe the application of algorithms to design reaction arrays on the basis of (dis)similarity to reactions that yield known bioactive molecules. It was envisaged that the reactions would be selected from a large virtual reaction space defined by all possible combinations of heteroaromatic substrates **4** (quinazolinones and related substrates) and aldehyde or ketone co-substrates **5** (Panel C). A bacterial growth inhibition assay would then be used to identify photocatalysed alkylations<sup>9</sup> that yield products (*e.g.* **6**) with antibacterial activity. The photocatalysed alkylation<sup>9a</sup> of quinazolinones with both aldehydes and ketones is well predated. It was therefore envisaged that, by using aryl-substituted co-substrates, this reaction may enable variation of the linker between the heterocyclic core and an appended aromatic ring.

<sup>a</sup>School of Chemistry, University of Leeds, Leeds, LS2 9JT, UK.

E-mail: a.s.nelson@leeds.ac.uk

<sup>b</sup>Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK<sup>c</sup>School of Molecular and Cellular Biology, University of Leeds, Leeds, LS2 9JT, UK† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2ob01404a>




**Scheme 1** Chemistry for activity-directed synthesis. Panel A: Rh-catalysed diazo chemistry exploited in the activity-directed synthesis of androgen receptor modulators; groups derived from a diazo substrate (black) and co-substrates (blue) are indicated. Panel B: Pd-catalysed carbonylation chemistry exploited in the activity-directed expansion of a series of antibacterials (B1); groups derived from an amine co-substrate (blue) and a carbon monoxide source (red) are indicated. The structure of an antibacterial quinazolinone that was discovered is shown, together with its activity against selected *S. aureus* strains (B2). Panel C: Envisaged photoredox-catalysed alkylation involving aldehyde/ketone co-substrates (blue).

## Results and discussion

### Establishment of a workflow for activity-directed synthesis

Initially, we established a workflow for the activity-directed synthesis of antibacterials based on photoredox-catalysed alkylation reactions<sup>9a</sup> conducted on a 300  $\mu$ l scale (3  $\mu$ mol limiting substrate) (Fig. 1). Accordingly, combinations of a quinoxalinone substrate (**S1** or **S2**; final concentration: 10 mM), an aldehyde/ketone co-substrate (**7**, **8** or **9**; final concentration: 300 mM), tris(trimethylsilyl)silane (TTMS) (final concentration: 20 mM), TFA (final concentration: 20 mM) and Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(dtbpy)PF<sub>6</sub> (final concentration: 0.1 mM) were assembled in vials from stock solutions in MeCN. The sealed vials were irradiated (36 W blue LED) at room temperature for 24 h, and the crude reaction mixtures were evaporated and redissolved in DMSO to give stock solutions (total product concentration: 10 mM). Adapted<sup>5</sup> standard susceptibility testing methodology<sup>10</sup> was used to assess antibacterial activity against two independent cultures of *S. aureus* ATCC29213<sup>11a</sup> at 10  $\mu$ M total product concentration in 99:1 Iso-Sensitest Broth<sup>12</sup>



**Fig. 1** Establishment of an activity-directed synthesis workflow. Panel A: substrates and aldehyde/ketone co-substrates used. Panel B: inhibition of growth of two independent cultures of *S. aureus* ATCC29213 (see Fig. 3 for colour scale) by reaction mixtures derived from specific substrate/co-substrate combinations (total product concentration: 10  $\mu$ M). Reactions were performed in microscale vials and involved a substrate (**S1** or **S2**; 10 mM), a co-substrate (**7**, **8** or **9**; 30 eq.), TTMS (2 eq.), TFA (2 eq.) and Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(dtbpy)PF<sub>6</sub>.


(ISB)–DMSO. Crucially, the combination of **S2** and aldehyde **8** (which would yield **3a**<sup>5</sup>) resulted in >99% growth inhibition, whereas the other five substrate/co-substrate combinations did not inhibit bacterial growth. In addition, the individual substrates (**S1** and **S2**), co-substrates (**7–9**), catalyst, TTMS and TFA were all subjected to the workflow at the appropriate concentrations, and the resulting crude mixtures were shown to not inhibit (<2%) bacterial growth (see ESI†). The workflow thus enabled both the synthesis of **3a**, and the detection of its antibacterial activity in a crude product mixture; and was deemed to be suitable for the activity-directed synthesis of antibacterials.

### Algorithm-driven activity-directed synthesis: Round 1

Initially, we defined a set of 20660 virtual reactions based on all possible combinations of 20 substrates and 1033 co-substrates (Fig. 2). The substrates **S1–S20** included analogues of quinoxalinones in which the benzo ring had been substituted or replaced with a heterocyclic variant (see ESI† and Fig. 4); 16 of the substrates were prepared from four commercially-available isotopic anhydrides, and the remaining four substrates from 2-amino nicotinic acid.<sup>13</sup> The possible aldehyde and ketone co-substrates were extracted from a set of commercially-available compounds, and were filtered to have 0–2 rotatable bonds, 8–15 heavy (non-hydrogen) atoms, 1–2 aromatic rings and no undesired functionality.

Next, we subjected the 20 substrates (**S1–S20**) to our activity-directed synthesis workflow. Here, “mock” reactions were performed in the absence of any co-substrate, and the crude reaction mixtures were evaluated at 10  $\mu$ M total product concentration; crucially, <2% bacterial growth inhibition was observed in all cases, which gave confidence that any observed activities






**Fig. 2** Overview of the definition of a large virtual reaction space, and the algorithm used to design the Round 1 reaction array based on the hit reaction (substrate **S2** + co-substrate **8**).

would be dependent on the presence of the specific co-substrate used.

An algorithm was then harnessed to design the reaction array that was executed in Round 1. Substrate combinations that were similar (Tanimoto coefficient based the ECFP4 fingerprints<sup>14</sup> for the substrate combinations >0.68) to the hit reaction (substrate **S2** + co-substrate **8**, see Fig. 1) were extracted from the large virtual reaction space. This yielded 357 reactions that could, in principle, be executed in Round 1. To identify 20 possible arrays of 30 reactions for execution, Pareto optimisation<sup>15</sup> was undertaken with two (conflicting) objectives: (a) to minimise the number of unique co-substrates that would need to be purchased; and (b) to maximise the diversity of the substrate/co-substrate combinations. It was decided to execute the designed reaction array that had the fewest unique co-substrates (Fig. 3, panel A).

A liquid handling robot was used to assemble the required combinations of substrates and co-substrates in the designed reaction array. Here, the appropriate substrate (100  $\mu$ l of a 30 mM solution in MeCN) and co-substrate (100  $\mu$ l of a 0.90 M solution in MeCN) were combined. Subsequently, TFA (25  $\mu$ l of a 0.24 M solution in MeCN), TTMS (25  $\mu$ l of a 0.24 M solution in MeCN) and Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(dtbpy)PF<sub>6</sub> (50  $\mu$ l of a 0.6 mM solution in MeCN) were added. The final concentration of the components in each 300  $\mu$ l reaction were therefore: substrate (10 mM), co-substrate (300 mM), TFA (20 mM), TTMS (20 mM) and catalyst (0.1 mM). In parallel, a control reaction array was also assembled in which the substrates (but not the co-substrates) were omitted. The sealed vials were irradiated at room temperature for 24 h, and the crude reaction mixtures were evaporated and redissolved in 300  $\mu$ l DMSO to give stock solutions with 10 mM total product concentration. The crude reaction mixtures were assayed against three independent cultures of *S. aureus* ATCC29213 at 10  $\mu$ M total product concentration in 99:1 ISB-DMSO. The difference in growth inhibition




**Fig. 3** Difference in growth inhibition by crude products of the designed reaction arrays, and the corresponding reactions in which the substrate was omitted (see ESI†). Reactions were performed in micro-scale vials and involved a substrate (**S1** or **S2**; 10 mM; omitted in control reaction arrays), a co-substrate (**7**, **8** or **9**; 30 eq.), TTMS (2 eq.), TFA (2 eq.) and Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(dtbpy)PF<sub>6</sub>. Crude products were assayed against three independent colonies of *S. aureus* ATCC29213 at 10  $\mu$ M total product concentration to yield hit reactions (yellow). Reaction products that displayed activity even in the absence of a substrate (pink, see ESI†) and combinations that were not investigated due to co-substrate unavailability (grey) are indicated. Panel A: reaction array in Round 1 designed on the basis of the hit reaction **S2/8** (see Fig. 1). Panel B: reaction array in Round 2 designed on the basis of hit reactions from Round 1.

between the crude products of the designed reactions, and the corresponding control reactions that lacked a substrate, is shown in Fig. 3, panel A.

The crude products of eight reactions resulted in >70% growth inhibition for all three cultures. However, for six of these reactions (that involved the co-substrates **C13**, **C494**, **C504**, **C661**, **C673** and **C933**), growth inhibition was also








**Fig. 5** Overview of the definition of a large virtual reaction space, and the algorithm used to design the Round 2 reaction array based on the hit reactions from Round 1.

had been performed in Round 1. It was decided to execute the reaction array with the fewest unique co-substrates.

Unfortunately, two of the required co-substrates (**C10900** and **C12019**) could not be readily prepared by oxidation of the corresponding primary alcohol, meaning that only 27 of the 30 designed reactions could actually be executed. Following execution of the reaction array, the crude reaction mixtures were assayed against three independent cultures of *S. aureus* ATCC29213 at 10  $\mu\text{M}$  total product concentration in 99 : 1 ISB–DMSO. The difference in growth inhibition between the crude products of the designed reactions, and the corresponding control reactions that lacked a substrate, is shown in Fig. 3, panel B. The crude products of six reactions resulted in >70% growth inhibition for all three independent cultures. However, for two of these reactions, involving the same co-substrate **C10957**, growth inhibition was also observed in the corresponding reactions in the control array that lacked a quinazolinone substrate. Thus, four new hit reactions were identified: the reaction between the quinazolinone **S2** and aldehydes **C10257**, **C10258** or **C11371**; and the reaction between the quinazolinone **S3** and the aldehyde **C10257**. A total of six hit reactions was thus identified across both rounds of activity-directed synthesis.

### Evaluation of the activity of purified products

For each of the identified hit reactions from Round 1 and 2, we prepared and purified samples of the anticipated alkylated products (Fig. 6 and Table 1). In addition, inspired by the hit combinations **S2/C10258**, **S3/C981** and **S3/C10257**, we also prepared the quinazolinone **3f** which would have been formed from **S3** and **C10258**, a combination that had not been explored. As controls, we prepared **3h** and **3i**, which would have been derived from two investigated combinations that were not identified as hits. The quinazolinones **3a**, **3d**, **3g**, **3h**



**Fig. 6** Structures of compounds for which MICs were determined (see Table 1).

**Table 1** Activity of compounds against three *S. aureus* strains (ATCC29213, USA300 JE2, SH1000). The range of MICs observed in duplicate is shown for each strain. To assess selective toxicity against bacteria, all compounds were also tested against yeast (*Candida albicans*, Ca6) at a fixed concentration of 16  $\mu\text{g mL}^{-1}$  and were found to be inactive

Compound	Hit?	MIC ( $\mu\text{g mL}^{-1}$ )		
		ATCC29213	USA300 JE2	SH1000
<b>3a<sup>a</sup></b>	√ (R1) ( <b>S2</b> , <b>C981</b> )	0.016	0.016	1–2
<b>3b<sup>b</sup></b>	√ (R2) ( <b>S2</b> , <b>C10257</b> )	0.5–1	0.5–1	4
<b>3c<sup>b</sup></b>	√ (R2) ( <b>S2</b> , <b>C10258</b> )	4	4	8
<b>3d<sup>a</sup></b>	√ (R2) ( <b>S2</b> , <b>C11371</b> )	0.016	0.016	1–2
<b>3e<sup>b</sup></b>	√ (R2) ( <b>S3</b> , <b>C10257</b> )	1	1	4
<b>3f<sup>b</sup></b>	c ( <b>S3</b> , <b>C10258</b> )	8	8	16
<b>3g<sup>a</sup></b>	√ (R1) ( <b>S3</b> , <b>C981</b> )	0.5–1	0.5–1	4
<b>3h<sup>a</sup></b>	x (R2) ( <b>S2</b> , <b>C11313</b> )	>256	>256	>256
<b>3i<sup>c</sup></b>	x (R2) ( <b>S3</b> , <b>C11313</b> )	>256	>256	>256

<sup>a</sup> Prepared by scale-up of the photoredox-catalysed alkylation reaction (see ESI<sup>†</sup>). <sup>b</sup> Prepared by an independent synthetic route (see ESI<sup>†</sup>). <sup>c</sup> The substrate and co-substrate were exploited in other hit reactions, but this specific combination was not explored in either array.

and **3i** were prepared by scale-up of the original photoredox-catalysed alkylation reaction, whereas **3b**, **3c**, **3e** and **3f** were prepared by an independent synthetic route.<sup>16</sup>

The quinazolinone products that corresponded to identified hit combinations had MIC values against *S. aureus* ATCC29213 ranging from 0.016  $\mu\text{g mL}^{-1}$  (for **3a** and **3d**) to 4  $\mu\text{g mL}^{-1}$  (for **3c**). Reassuringly, **3h** and **3i**, which corresponded to investigated combinations that were not identified as hits, did not inhibit bacterial growth, even at 256  $\mu\text{g mL}^{-1}$ . **3f**, which corresponded to a substrate/co-substrate combination that was not explored (but, instead was inspired by three other hit com-



binations, see above) had an MIC value of 8–16  $\mu\text{g ml}^{-1}$ . All of the analogues **3a–3i** were also screened against the methicillin-resistant USA300 JE2 strain<sup>11b</sup> and the laboratory strain<sup>11c,d</sup> SH1000 (see Table 1 and Discussion). They were also evaluated against yeast (*Candida albicans* Ca6) and were found to be inactive at 16  $\mu\text{g ml}^{-1}$ .

## Discussion

We had previously hypothesised that the integrated and parallel nature of its workflows might enable activity-directed synthesis to be algorithm-driven.<sup>1,8</sup> We have now demonstrated that algorithms can indeed drive the activity-directed synthesis of bioactive small molecules. The use of these algorithms does mean that designed reaction arrays no longer involve all combinations of components; this means that it is more convenient to use a liquid handling robot to assemble the designed arrays, rather than manually using multi-channel pipettes.

We have also shown that it was feasible for a photoredox-catalysed reaction to underpin activity-directed synthesis, a reaction class that has potential to explore diverse regions of chemical space.<sup>17</sup> As with other activity-directed synthesis workflows,<sup>3–6</sup> it was critical that appropriate control reactions were performed to give confidence that observed activities stemmed from the specific substrate/co-substrate combination used. In this study, the use of control arrays enabled identification of co-substrates whose reactions yielded apparently antibacterial products even in the absence of a substrate. In addition, it was, of course, also important to purify, elucidate and characterise the products of identified hit reactions.

Our approach enabled expansion of a series<sup>7</sup> of antibacterial quinazolinones. These compounds had comparable activity against *S. aureus* ATCC29213 and the methicillin-resistant USA300 JE2 strain, but were generally significantly less active against the laboratory strain SH1000. It was demonstrated that limited variation of the *meta*-substituted phenyl ring of **3a**<sup>5</sup> was possible: the corresponding *m*-acetamidophenyl-substituted analogue (**3g**) retained significant antibacterial activity. However, none of the reactions involving substrates other than **S2** or **S3** – for example, quinazolinones with replaced/substituted benzo rings or other phenyl substituents – resulted in any growth inhibition at the concentration tested (total product concentration: 10  $\mu\text{M}$ ). Some variation of the substitution of the phenyl ring of the 2-phenylethyl group of **3a** was, however, possible: the quinazolinones **3c** and **3f** (with a 4-*tert*-butylphenyl group); **3b** and **3e** (with a 3,4-difluorophenyl group); and **3d** (with a 2,4,6-trimethylphenyl group) displayed significant antibacterial activity. Indeed, the activity of **3d** (with its 2,4,6-trimethylphenyl group) (MIC against ATCC 29213 : 0.016  $\mu\text{g ml}^{-1}$ ) was comparable with that of **3a**. It was notable that no reactions that involved any of the other seven substituted phenyl acetaldehydes used, nor the homologated aldehyde **C11313**, resulted in the formation of antibacterial products. Although two reactions of the homologated aldehyde




Fig. 7 Summary of expanded structure–activity relationships.

**C11313** were shown to be productive, yielding the corresponding homologated products (**3h** and **3i**), neither of these products displayed detectable antibacterial activity (MIC against *S. aureus* ATCC 29213 : >256  $\mu\text{g ml}^{-1}$ ). It was therefore concluded that the length of the 2-phenylethyl side chain was critical, and that only limited range of substituents on the phenyl ring of this side chain was tolerated.

A summary of the structure–activity-relationships of the antibacterial quinazolinones is provided in Fig. 7. Whilst the approach was certainly valuable for the rapid generation of these relationships, it is, perhaps, disappointing that it was not possible to expand the series of antibacterial quinazolinones<sup>7</sup> more extensively, perhaps because this series has already been largely optimised. Within an ADS workflow, the choice of screening concentration(s) is critical. Here the crude products were screened at 10  $\mu\text{M}$  total product concentration.‡ This choice of screening concentration meant that the least active product identified was **3c** (whose MIC against *S. aureus* ATCC29213 is 4  $\mu\text{g ml}^{-1}$  *i.e.* ~8  $\mu\text{M}$ ). At this screening concentration, less active products would not have been detected, even if formed in high yield. In retrospect, it may have been helpful to have screened at higher total product concentration (s) in Round 1. This may have enabled the identification of more diverse, yet synthetically accessible, products with significant (albeit lower) antibacterial activity. These hit reactions could then have informed the design of a more diverse reaction array in Round 2.

## Conclusions

We have shown that the design of reaction arrays within ADS workflows may be algorithmically-driven. Here, the execution of reaction arrays, whose design was based on the similarity of substrate/co-substrate combinations to those known to yield bioactive products, enabled expansion of a series of antibacterial quinazolinones. The approach enabled efficient definition of the structure–activity relationships for this compound series. The compounds had comparable activity against *S. aureus* ATCC29213 and the methicillin-resistant USA300 JE2 strain, though were generally significantly less active against

‡ We did also investigate screening at 0.1 and 1 (M total product concentration, but no new hits were detected at these lower concentrations.



the laboratory strain SH1000; crucially, they displayed selective toxicity against bacteria, and were not active against yeast. In addition, it was demonstrated that ADS could be underpinned by photoredox-catalysed reactions, a reaction class that can enable diverse chemical space to be explored. Overall, it is envisaged that algorithms may ultimately enable the fully autonomous activity-directed discovery of small molecules with a wide range of biological functions.

## Author contributions

The research was conceptualised by AN, AJO'N and SW; supervised by AN, AJO'N, SW and AL; and performed by DF, SF, AM, DD and AN. This paper was drafted by AN, and reviewed and edited by all authors.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We thank EPSRC (EP/N025652/1) and University of Leeds for support; Eduardo Rico for discussions and assistance; and Sam Liver, Sam Griggs, Chris Arter and George Karageorgis for helpful discussions. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.

## References

- G. Karageorgis, S. Liver and A. Nelson, *ChemMedChem*, 2020, **15**, 1776.
- For a conceptually-related approach known as synthetic fermentation, see. (a) I. A. Stepek and J. W. Bode, *Curr. Opin. Chem. Biol.*, 2018, **46**, 18; (b) Y.-L. Huang and J. W. Bode, *Nat. Chem.*, 2014, **6**, 877; (c) J. G. Hubert, I. A. Stepek, H. Noda and J. W. Bode, *Chem. Sci.*, 2018, **9**, 2159; (d) I. A. Stepek, T. Cao, A. Koetemann, S. Shimara, B. Wollscheid and J. W. Bode, *ACS Chem. Biol.*, 2019, **14**, 1030.
- G. Karageorgis, S. Warriner and A. Nelson, *Nat. Chem.*, 2014, **6**, 872.
- G. Karageorgis, M. Dow, A. Aimon, S. Warriner and A. Nelson, *Angew. Chem., Int. Ed.*, 2015, **54**, 13538.
- A. Leggott, J. E. Clarke, S. Chow, S. L. Warriner, A. J. O'Neill and A. Nelson, *Chem. Commun.*, 2020, **56**, 8047.
- A. Green, F. Hobor, C. Tinworth, S. Warriner, A. Wilson and A. Nelson, *Chem. – Eur. J.*, 2020, **26**, 10682.
- (a) R. Bouley, D. Ding, Z. Peng, M. Bastian, E. Lastochkin, W. Song, M. A. Suckow, V. A. Schroeder, W. R. Wolter, S. Mobashery and M. Chang, *J. Med. Chem.*, 2016, **59**, 5011; (b) S. Gatadi, T. V. Lakshmi and S. Nanduri, *Eur. J. Med. Chem.*, 2019, **170**, 157; (c) Y. Qian, *et al.*, *J. Med. Chem.*, 2020, **63**, 5287.
- S. Chow, S. Liver and A. Nelson, *Nat. Rev. Chem.*, 2018, **2**, 174.
- (a) J. Dong, Z. Wang, X. Wang, H. Song and Q. Wang, *Sci. Adv.*, 2019, **5**, eaax9955; (b) X. Ji, Q. Liu, Z. Wang, P. Wang, G. Deng and H. Huang, *Green Chem.*, 2020, **22**, 8233; (c) Z. Wang, Q. Liu, X. Ji, G. Deng and H. Huang, *ACS Catal.*, 2019, **10**, 154; (d) Z. Wang, X. Ji, J. Zhao and H. Huang, *Green Chem.*, 2019, **21**, 5512.
- F. R. Cockerill III, M. A. Wikler, J. Alder, M. N. Dudley, G. M. Eliopoulos, M. J. Ferraro, D. J. Hardy, D. W. Hecht, J. A. Hindler, J. B. Patel, M. Powell, J. M. Swenson, R. B. Thomson Jr., M. Traczewski, J. D. Turnidge, M. P. Weinstein and B. L. Zimmer, *CLSI M07-A9: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically*, Clinical and Laboratory Standards Institute, 2012, 9th edn.
- (a) I. Soni, H. Chakapani and S. Chopra, *Genome Announc.*, 2015, **3**, e01095-15; (b) P. D. Fey, J. L. Endres, V. K. Yajjala, T. J. Widhelm, R. J. Boissy, J. L. Bose and K. W. Bayles, *mBio*, 2013, **4**, e00537-12; (c) M. J. Horsburgh, J. L. Aish, I. J. White, L. Shaw, J. K. Lithgow and S. J. Foster, *J. Bacteriol.*, 2002, **184**, 5457; (d) A. J. O'Neill, *Lett. Appl. Microbiol.*, 2010, **51**, 358.
- D. J. Farrell, M. Robbins, W. Rhys-Williams and W. G. Love, *Antimicrob. Agents Chemother.*, 2010, **55**, 1177.
- (a) D. Kumar, P. Jadhavar, M. Nautiyal, H. Sharma, P. Meena, L. Adane, S. Pancholia and A. Chakraborti, *RSC Adv.*, 2015, **5**, 30819; (b) P. Jadhavar, T. Dharmeliya, M. Vaja, D. Kumar, J. Sridevi, P. Yogeewari, D. Sriram and A. Chakraborti, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 2663.
- D. Rogers and M. Hahn, *J. Chem. Inf. Model.*, 2010, **50**, 742.
- N. Gunantara and Q. Ai, *Cogent Eng.*, 2018, **5**, 1502242.
- S. Gatadi, J. Gour, M. Shukla, G. Kaul, S. Das, A. Dasgupta, S. Malasala, R. Borra, Y. Madhavi, S. Chopra and S. Nanduri, *Eur. J. Med. Chem.*, 2018, **157**, 1056.
- (a) M. H. Shaw, J. Twilton and D. W. C. MacMillan, *J. Org. Chem.*, 2016, **81**, 6989; (b) N. A. Romero and D. A. Nicewicz, *Chem. Rev.*, 2016, **116**, 10075; (c) J. M. R. Narayanam and C. R. J. Stephenson, *Chem. Soc. Rev.*, 2011, **40**, 102; (d) M. D. Kärkäs, J. A. Porco and C. R. J. Stephenson, *Chem. Rev.*, 2016, **116**, 9683; (e) L. Capaldo, D. Ravelli and M. Fagnoni, *Chem. Rev.*, 2021, **122**, 1875; (f) P. Murray, J. Cox, N. Chiappini, C. Roos, E. McLoughlin, B. Hejna, S. Nguyen, H. Ripberger, J. Ganley, E. Tsui, N. Shin, B. Koronkiewicz, G. Qiu and R. Knowles, *Chem. Rev.*, 2021, **122**, 2017.

